Omeros director granted 15,000 stock options

Omeros Corporation director Peter A. Demopulos received a grant of stock options to buy 15,000 shares of common stock at an exercise price of $10.28 per share.

Rhea-AI Filing Summary

Omeros Corporation director Peter A. Demopulos received a grant of stock options to buy 15,000 shares of common stock at an exercise price of $10.28 per share. The options were awarded under the company’s non-employee director compensation policy and will fully vest the day before the 2027 annual shareholder meeting if he continues serving as a director.

Insider Trade Summary

Grant/Award: 15,000 shares

Grant/Award 1 txn

Insider Demopulos Peter A MD

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	15,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 15,000 contracts (Direct)

Footnotes (2)

1. F1. Pursuant to Omeros Corporation's non-employee director compensation policy, on the date of each annual meeting of shareholders, each non-employee director who has served as a director for at least six months and who will continue to serve as a director after the annual meeting is automatically granted an option to purchase 15,000 shares of common stock. This Form 4 reports the annual stock option award granted to the reporting person in conjunction with the annual meeting of shareholders held on June 18, 2026.
2. F2. This option will fully vest and become exercisable on the day before the date of the 2027 annual meeting of the shareholders of Omeros Corporation, provided that the reporting person continues to serve as a director of the company through such date.

Key Figures

Option grant size: 15,000 options Exercise price: $10.28 per share Underlying shares: 15,000 shares +2 more

5 metrics

Option grant size 15,000 options Stock Option (Right to Buy) granted June 18, 2026

Exercise price $10.28 per share Conversion or exercise price of granted options

Underlying shares 15,000 shares Common Stock underlying the stock option award

Post-grant option holdings 15,000 options Total derivative securities following this transaction

Option expiration June 17, 2036 Expiration date of the granted stock options

Key Terms

non-employee director compensation policy, stock option, annual meeting of shareholders, vest and become exercisable, +1 more

5 terms

non-employee director compensation policy financial

"Pursuant to Omeros Corporation's non-employee director compensation policy, on the date of each annual meeting..."

stock option financial

"each non-employee director ... is automatically granted an option to purchase 15,000 shares of common stock."

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

annual meeting of shareholders financial

"granted to the reporting person in conjunction with the annual meeting of shareholders held on June 18, 2026."

A yearly gathering where a company’s owners (shareholders) vote on key items like electing the board, approving executive pay, and ratifying auditors, and receive updates on performance and strategy. Think of it as an annual town hall for owners: it matters to investors because outcomes and disclosures can affect leadership, corporate direction, dividend and governance policies, and therefore the company’s risk and potential return.

vest and become exercisable financial

"This option will fully vest and become exercisable on the day before the date of the 2027 annual meeting..."

expiration date financial

"expiration_date: 2036-06-17T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did OMER director Peter A. Demopulos report on this Form 4?

He reported receiving a grant of stock options for 15,000 shares of Omeros common stock. The award is part of the company’s non-employee director compensation policy and represents a routine equity-based compensation grant, not an open-market stock purchase or sale.

What is the exercise price of the new OMER stock options?

The granted stock options have an exercise price of $10.28 per share. This means Demopulos can buy Omeros common stock at $10.28 once the options vest, regardless of the market price at that future time, subject to the plan’s terms.

How many OMER shares are covered by the new stock option award?

The option grant covers 15,000 underlying shares of Omeros common stock. Following this transaction, the filing shows Demopulos holding 15,000 stock options, reflecting this single reported award under the non-employee director compensation policy.

When do Peter A. Demopulos’s new OMER options vest and become exercisable?

These options will fully vest and become exercisable on the day before the 2027 annual meeting of shareholders. Vesting is contingent on Demopulos continuing to serve as a director of Omeros through that date, according to the disclosed footnote terms.

Why did OMER grant 15,000 stock options to its director on June 18, 2026?

The grant was made under Omeros Corporation’s non-employee director compensation policy. Under this policy, each eligible non-employee director automatically receives an option to purchase 15,000 shares on the date of each annual shareholder meeting, assuming ongoing board service.

Was this OMER Form 4 transaction a market purchase or sale of shares?

No, this Form 4 reports a grant of stock options, not a market trade. The options were awarded at no cost as director compensation and only give Demopulos the right to buy shares later at the fixed $10.28 exercise price once vested.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/22/2026 - 07:33 AM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Demopulos Peter A MD

(Last) (First) (Middle)

201 ELLIOTT AVENUE WEST

(Street)

SEATTLE WASHINGTON 98119

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
OMEROS CORP [ OMER ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)(1)	$10.28	06/18/2026		A		15,000		(2)	06/17/2036	Common Stock	15,000	$0	15,000	D

Explanation of Responses:

1. Pursuant to Omeros Corporation's non-employee director compensation policy, on the date of each annual meeting of shareholders, each non-employee director who has served as a director for at least six months and who will continue to serve as a director after the annual meeting is automatically granted an option to purchase 15,000 shares of common stock. This Form 4 reports the annual stock option award granted to the reporting person in conjunction with the annual meeting of shareholders held on June 18, 2026.

2. This option will fully vest and become exercisable on the day before the date of the 2027 annual meeting of the shareholders of Omeros Corporation, provided that the reporting person continues to serve as a director of the company through such date.

	/s/ Peter B. Cancelmo, Attorney-in-Fact	06/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)